Our study found a significant association between platinum-based drugs and inflammatory myopathies such as dermatomyositis and polymyositis. Among these drugs, carboplatin is associated with extensive muscle damage. Platinum-based drugs have a higher incidence of specific adverse reactions, such as muscle abscesses and myositis, compared to other drugs in this class. Advanced age and the use of carboplatin are considered independent high-risk factors for the development of these conditions. Bio-pathway analysis results indicate that platinum-induced muscle damage involves disruptions in energy metabolism and immune response, suggesting potential mechanisms for platinum-induced muscle inflammation.